Ustekinumab biosimilar is under clinical development by STgen Bio and currently in Pre-Registration for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Pre-Registration drugs for Plaque Psoriasis (Psoriasis Vulgaris) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Ustekinumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Ustekinumab biosimilar overview

Ustekinumab biosimilar is under development for the treatment of plaque psoriasis, Crohn's disease, psoriatic arthritis and ulcerative colitis. It is administered through subcutaneous route. The drug candidate acts by targeting interleukin 12 subunit beta and interleukin 23 subunit alpha.

STgen Bio overview

STgen Bio, formerly DM Bio, is a bio pharmaceutical manufacturing company involved in providing various contract manufacturing services ranging from pre-clinical services to sale of in market bio pharmaceutical products. The company is headquartered in Incheon, Seoul, South Korea.

For a complete picture of Ustekinumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.